GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Net Change in Cash

Heidelberg Pharma AG (XTER:HPHA) Net Change in Cash : €-14.11 Mil (TTM As of Aug. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Heidelberg Pharma AG's Net Change in Cash for the three months ended in Aug. 2024 was €-6.05 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Aug. 2024 was €-14.11 Mil.

Heidelberg Pharma AG Net Change in Cash Historical Data

The historical data trend for Heidelberg Pharma AG's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Net Change in Cash Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.56 -4.90 1.16 75.19 -37.89

Heidelberg Pharma AG Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.70 -7.24 -10.79 9.97 -6.05

Heidelberg Pharma AG Net Change in Cash Calculation

Heidelberg Pharma AG's Net Change in Cash for the fiscal year that ended in Nov. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-33.672+5.848+-10.053+-0.014
=-37.89

Heidelberg Pharma AG's Net Change in Cash for the quarter that ended in Aug. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-5.824+-0.182+-0.038+-0.005
=-6.05

Net Change in Cash for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Net Change in Cash
Comparable Companies
STU:T9G XTER:MDG1 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE UTHR MRNA SMMT INCY OCSE:GMAB INSM SHSE:603392 BMRN
Traded in Other Exchanges
0QW5:UK
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Website
https://www.heidelberg-pharma.com
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Walter Miller Board of Directors
Dr. Georg F. Baur Supervisory Board
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG Headlines

No Headlines